The departure and replacement of the Principal Accounting Officer is a standard succession event with no expected disruption to financial reporting or operations. Monitor for any subsequent changes in the finance team, but no immediate trading action is warranted.
RCKT drugs
RCKT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 1 $3.52entry
- T+1 · 5mo ago +9.09%α +9.22% · $3.84
- T+5 · 4mo ago +15.63%α +15.36% · $4.07
- T+20 · 4mo ago −10.80%α −8.61% · $3.14
- T+60 · 8w ago −23.58%α −26.45% · $2.69
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rocket Pharmaceuticals disclosed the resignation of VP of Finance and Principal Accounting Officer John Militello, effective July 7, 2026, to pursue other opportunities. Joseph Manhede, the company's Associate VP of Corporate Controller since April 2026, was appointed as the new Principal Accounting Officer effective July 8, 2026. This is a routine internal succession with no material financial or operational impact.
Key Facts
- John Militello resigned as VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer, effective July 7, 2026.
- Joseph Manhede appointed as Principal Accounting Officer effective July 8, 2026.
- Manhede has served as Associate VP, Corporate Controller since April 2026 and has prior experience at Outlook Therapeutics, Amneal Pharmaceuticals, and Deloitte.
- No new compensatory arrangements were entered into with Manhede in connection with the appointment.
Financial Impact
No financial impact; routine officer change with no compensation changes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-026982 |
| Document: 0001140361-26-026982-index-headers.html | 0001140361-26-026982 |
| Document: 0001140361-26-026982-index.html | 0001140361-26-026982 |
| Document: 0001140361-26-026982.txt | 0001140361-26-026982 |
Track record
21 reports on RCKT
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers